Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2.

BACKGROUND: Anastrozole is a non-steroidal fourth generation aromatase inhibitor that stops the conversion of testosterone to estradiol and has been used as empiric medical therapy for the treatment of male infertility in men with an abnormal testosterone-to-estradiol ratio <10 in order to increase endogenous testosterone levels. This study sought to evaluate the efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index greater than 25 mg/kg2 with respect to hormonal profile, semen parameters and overall fertility status.
METHODS: Retrospective chart review was performed of hypogonadal, subfertile men with body mass index ≥25 kg/m2 who were treated with anastrozole (1 mg daily). Hormonal measurements and semen analysis prior to and after treatment was analyzed in 30 men. Total motile count was calculated from semen analysis. Clinical pregnancy rates were recorded.
RESULTS: Men treated with anastrozole had increases in follicle stimulating hormone (4.8 versus 7.6 IU/L, P<0.0001), luteinizing hormone (3.4 versus 5.4 IU/L, P<0.0001), testosterone (270.6 versus 412 ng/dL, P<0.0001) and testosterone-to-estradiol ratio (9 versus 26.5, P<0.0001) and decrease in estradiol level (32 versus 15.9 pg/mL, P<0.01) after 5 months of therapy. Increases in sperm concentration (7.8 versus 14.2 million/mL, P<0.001), total motile count (12.6 versus 17.7 million, P<0.01) and strict morphology (3.0% versus 3.5%, P<0.05) was appreciated. Clinical pregnancy rate for our cohort was 46.6% (14 of 30), with 71.4% (10 of 14) conceiving through in vitro fertilization, 14.2% (2 of 14) through intrauterine insemination and 14.2% (2 of 14) through natural intercourse.
CONCLUSIONS: Anastrozole improves hormonal profiles and semen parameters in hypogonadal, subfertile men with body mass index over 25 kg/m2 and may aid in achieving pregnancy especially in conjunction with assisted reproductive techniques. 2021 Translational Andrology and Urology. All rights reserved.

Introduction

Approximately 15% of couples have difficulty achieving pregnancy after one year of unprotected intercourse, with impaired sperm quality or production contributing as a male factor in 30% to 50% of all infertile couples (1-3). Thirty to 70% of men with male infertility have some degree of endocrine dysfunction (4,5) with 43% prevalence of hypogonadism observed in men with oligospermia (6). Because spermatogenesis is dependent upon on high levels of intratesticular testosterone (7), empiric medical therapy for male infertility such as aromatase inhibitors has been used to increase endogenous testosterone levels in order to improve spermatogenesis (3).

Aromatase is a cytochrome P-450 enzyme that converts testosterone to estradiol and androstenedione to estrone, respectively. It is found in female reproductive tissue, adipose tissue, testes, liver and brain (8). Aromatase inhibitors suppress the peripheral metabolism of testosterone to estradiol which in turn leads to increased testosterone levels and decreased estrogen levels. The combined effect of increasing endogenous testosterone helps to further stimulate spermatogenesis while lower estrogen levels helps to minimize its inhibitory effect on the hypothalamic-pituitary-gonadal (HPG) axis.

Anastrozole is a nonsteroidal aromatase inhibitor that causes reversible enzyme inhibition and has been shown to improve hormonal profile and semen parameters in male factor infertility patients (8-10). However, its effect in overweight or obese, subfertile men is unknown. Obesity has been postulated to contribute to endocrine dysfunction in male factor infertility in a variety of ways, most notably estrogen excess from the peripheral aromatization of testosterone to estrogen in adipose tissue leading to a direct inhibitory effect on the HPG axis with subsequent impairment of spermatogenesis (11). A systematic review conducted by Campbell et al. demonstrated that obese men were more likely to experience infertility, decreased rates of live births associated with assisted reproductive technology (ART) and increased risk of pregnancy non-viability (12). In addition, obese men have been shown to have increased percentage of sperm with low mitochondrial membrane potential, DNA fragmentation, and abnormal morphology further affecting fertility potential (13).

The purpose of our study was to examine the responses in hormonal profile, semen parameters and overall fertility status over time following the initiation of anastrozole in subfertile men with body mass index (BMI) greater than 25 kg/m2. We present the following article in accordance with the STROBE reporting checklist (available at http://dx.doi.org/10.21037/tau-20-919).

Methods

All patients presented to 1 author (DS). Hypogonadal, subfertile men with BMI ≥25 kg/m2 who were treated with anastrozole (1 mg daily) between 2008 and 2014 were included in this study as BMI ≥25 kg/m2 is considered overweight. Indication for anastrozole therapy included testosterone level <300 ng/dL or bioavailable testosterone <155 ng/dL. Exclusion criteria were men with past exogenous testosterone use or with abnormal results on karyotype analysis, Y chromosome microdeletion or cystic fibrosis genetic analysis.

Data on demographics (age, BMI), medical history, genitourinary physical examination, adverse events, serum hormonal evaluation, liver function test (LFT), complete blood count (CBC) and semen analyses were collected prior to and after initiation of treatment. Hormonal concentrations, LFT and CBC levels were obtained before treatment and at 1 month, 3 month and 5 months after prescribing anastrozole. Hormonal analysis was attempted to be obtained between 7:00 am and 11:00 am by venipuncture. Hormonal evaluation included assessment of serum follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), estradiol (E), albumin, sex hormone binding globulin (SHBG) and prolactin. Commercially available laboratories were used for the hormonal testing and testosterone was measured via chemiluminescent immunoassays. Only patients with complete hormonal profile and semen analysis data for the study time points were included.

Semen analysis were performed before treatment and at 5 months after treatment. Semen samples were collected after an abstinence period of 2–5 days and processed within 1 hour of ejaculation. Semen analysis parameters that were analyzed included volume of ejaculate (mL), sperm concentration (million per mL), motility (percent) and strict morphology (percent).

Statistical analysis

Data from evaluable patients were presented using descriptive statistics as follows: continuous variables were summarized as mean (standard deviation) when the data were normally distributed and expressed as median (interquartile range: 25th–75th percentile) for non-normally distributed data. The assumption of normality was assessed using Shapiro-Wilk test. Categorical variables were presented as frequency (percentage). Comparison of continuous variables between independent groups was conducted using independent sample two-sided t-test or Wilcoxon rank sum test, as appropriate. We tested whether there was a difference in FSH, LH, testosterone and estradiol at baseline compared to levels reported at 1, 3 and 5-month follow-up visits using a two-sided t-test or Wilcoxon signed-rank, sign test, as appropriate. Comparison of categorical variables was performed using Fisher’s exact test or Pearson’s chi-square test, as appropriate. Any P<0.05 was considered statistically significant. All data analysis was performed using the statistical software SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA).

The study was conformed to the provisions of the Declaration of Helsinki (as revised in 2013) and approved by the Ethics Committee of Hackensack University Medical Center/Institutional Review Board (IRB number: Pro00006190). Because of the retrospective nature of the research, the requirement for informed consent was waived.

Results

Out of 53 total men, 30 subfertile men who met inclusion criteria were treated with anastrozole with follow-up hormonal analyses performed at 1, 3, and 5 months and follow-up semen analysis performed at 5 months. Baseline characteristics of the study population are as follows (): mean age was 34 years, mean age of partner was 33 years, and mean BMI was 28.7 with 18 individuals being overweight (BMI 25–30) and 12 individuals being obese (BMI >30). For patients with known smoking history, 25 of the 28 patients were non-smokers. In addition, 26.6% [8] of patients presented with at least grade 1 left varicocele, and 6% (2) of patients presented with at least a grade 1 right varicocele. 90% [27] suffered from primary infertility and 10% [3] suffered from secondary infertility.

Table 1

Baseline demographics of study population treated with anastrozole

Demographic	Value
Age (years), median (IQR) (range)	34.0 (33.0–38.0) (26.0–62.0)
Partner age (years), mean (SD) (range)	33.0 (3.7) (26.0–42.0)
Weight (lbs), median (IQR) (range)	202.5 (180.0–235.0) (155.0–400.0)
Height (in), mean (SD) (range)	70.0 (3.7) (60.0–80.0)
BMI (kg/m2), median (IQR) (range)	28.7 (26.6–32.2) (25.1–54.2)
Time since infertility diagnosis (years), median (IQR) (range)	1.0 (1.0–3.0) (0.3–7.0)
Smoking status, yes/no	3/25
Left varicocele (Grade 1 or higher), yes/no	8/22
Right varicocele (Grade 2 or higher), yes/no	2/28
Primary infertility, yes/no	27/3 (secondary infertility)

Lbs, pounds; In, inches; IQR, interquartile range; SD, standard deviation.

In , baseline hormonal levels are compared with those attained at 1, 3 and 5 months. Focusing on the 5-month hormonal profiles, there was a mean increase in testosterone (270.6 versus 412 ng/dL, P<0.0001), a mean decrease in estradiol (32 versus 15.9 pg/mL, P=0.0059), a mean increase in testosterone-to-estradiol (T/E) ratio (9 versus 26.5, P<0.0001), a mean increase in the gonadotropin LH (3.4 versus 5.4 IU/L, P<0.0001), and a mean increase in the gonadotropin FSH (4.8 versus 7.5 IU/L, P<0.0001). The aforementioned trends were statistically significant at 1-month and 3-month follow-ups as well. No statistically significant difference was noted between baseline hematocrit and those measured at 1, 3 and 5 months.

Table 2

Hormonal analysis of men treated with anastrozole

Hormones	Baseline	Month 1	P	Month 3	P	Month 5	P
Testosterone (ng/dL)‡	270.6 (68.0)	480.4 (137.5)	<0.0001	460.7 (134.8)	<0.0001	412.0 (133.1)	<0.0001
Estradiol (pg/mL)†	32.0 (20.9–32.0)	21.4 (12.6–32.0)	0.0085	17.8 (15.0–32.0)	0.0012	15.9 (15.0–31.5)	0.0059
T/E ratio†	9.0 (6.1–14.2)	23.8 (14.4–42.0)	<0.0001	23.1 (14.5–33.7)	<0.0001	26.5 (14.0–46.4)	<0.0001
FSH (IU/L)†	4.8 (2.5–7.1)	–	–	7.3 (4.1–10.2)	<0.001	7.5 (5.6–9.7)	<0.0001
LH (IU/L)†	3.4 (2.5–5.2)	–	–	5.2 (3.7–9.0)	<0.0001	5.4 (3.3–7.9)	0.0003

†Median (IQR, interquartile range; 25th–75th percentile); ‡Mean (SD, standard deviation); paired data differences: Month 1-Baseline, Month 3-Baseline, Month 5-Baseline were examined using 1-sample t-test or Wilcoxon signed rank test or Sign test. T/E, testosterone/estradiol; FSH, follicle stimulating hormone; LH, luteinizing hormone.

The baseline semen parameters were also compared to semen parameters at 5 months. Significant increases were demonstrated in sperm concentration (7.8 versus 14.2 million/mL, P=0.0003), total motile count (12.6 versus 17.7 million, P=0.0052), and sperm morphology (3.0% vs. 3.5%, P=0.0488). No significant changes from baseline were noted for semen volume and sperm motility ().

Table 3

Semen parameters in subfertile males treated with anastrozole

Semen parameter	Baseline	Month 5	Actual change from baseline	% change from baseline	P value
Volume (mL)
Median (IQR)	3.0 (1.7–4.5)	3.3 (1.5–4.6)	0.0 (−0.5–0.8)	0.0 (−21.2–32.0)	0.7670†
Concentration (million/mL)
Median (IQR)	7.8 (2.6–19.6)	14.2 (5.5–34.0)	5.2 (0.7–14.8)	52.8 (30.0–275.0)	0.0003‡
Motility (%)
Mean (SD)	42.4 (21.1)	47.9 (15.7)	5.5 (17.3)	9.7 (−12.7–117.4)	0.0907§
Total motile count (million)
Median (IQR)	12.6 (1.3–32.1)	17.7 (4.0–53.5)	3.6 (0.0–12.7)	91.6 (31.3–492.0)	0.0052‡
Strict morphology (%)
Median (IQR)	3.0 (1.0–4.0)	3.5 (1.0–6.0)	1.0 (0.0–3.0)	25.0 (0.0–100.0)	0.0488†

IQR, interquartile range; 25th–75th percentile; SD, standard deviation; †, paired data difference Month 5–Baseline, examined using Wilcoxon signed rank test; ‡, paired data difference, Month 5–Baseline, examined using Sign test; §, paired data difference, Month 5–Baseline, examined using 1-sample t-test.

Overall pregnancy rate for our cohort was 46.6% (14 of 30). Of the couples who achieved pregnancy, 71.4% (10 of 14) conceived through in vitro fertilization, 14.2% (2 of 14) through intrauterine insemination and 14.2% (2 of 14) through natural intercourse. Anastrozole was well tolerated with mild side effects reported by only 3 patients out of 30:1 patient had minor headaches, 1 patient had mild malaise and 1 patient had elevated liver function tests.

Discussion

Spermatogenesis is a highly regulated process involving complex multifactorial hormonal regulation. The importance of intratesticular testosterone for male germ cell development is well established, but the complex effects of estrogen is still being elucidated. In general, the cumulative effects of estrogen are largely inhibitory; however, specific lower concentrations must be maintained to promote adequate spermatogenesis. The most understood inhibitory role of estrogens is on the hypothalamus and pituitary gland, leading to decreased gonadotropins (LH and FSH). Estrogens also exhibit autocrine and paracrine effects on the testicular interstitium (Sertoli and Leydig cells). For instance, estrogens can modulate precursor populations of Leydig cells and reduce the stimulatory effects of LH on these cells causing decreased T production. Conversely, estrogens (along with FSH) promote spermatogenesis by aiding Sertoli cells in spermatogonia recognition and maturation. Hence, the role of estrogens in spermatogenesis is complex, but it is reasonable to conclude that high concentrations lead to decreased sperm quantity and quality (14-17).

The testosterone to estrogen ratio (T/E) provides a simple, quantitative comparison of these hormone concentrations. The T/E ratio was most notably used first by Pavlovich et al. to compare hormonal variations between infertile and fertile men (1). In this study, participants with severe male factor infertility had a mean T/E ratio of 6.9, while controls had a mean ratio of 14.5. A cutoff of 10 as the lower limit of normal was subsequently established, which represented the 20th percentile of T/E ratios in that study. In our current investigation, we used this value to delineate normal versus abnormal T/E ratios.

An abnormally low T/E ratio can be caused by decreasing testosterone, increasing estrogen, or more likely a combination of both processes. Hammoud et al. reported decreased sperm concentration in obese men to be associated with repeat polymorphism rate of TTTA nucleotides in the aromatase gene (11). Thus, one can infer that the overexpression of aromatase, a cytochrome P-450 enzyme that converts testosterone to estradiol and androstenedione to estrone, can lead to decreased T and increased E. Aromatase is found throughout the body including the female reproductive tract, testis, liver, brain, and adipose tissue (2,3). In the overweight (BMI 25–29.9 mg/kg2) and obese (BMI ≥30 mg/kg2) cohorts investigated in this study, the excess adipose tissue may contribute to the abnormal hormonal status, depressed semen parameters, and ultimately, their subfertility.

Anastrozole is a non-steroidal fourth generation aromatase inhibitor that was first approved in 1995 for the treatment of estrogen receptor positive breast cancer refractory to tamoxifen (18). Due to its mechanism of action that stops the conversion of testosterone to estradiol, anastrozole has also been used off label for the treatment of male infertility in males with an abnormal T/E ratio <10 in order to increase endogenous testosterone levels, with subsequent improvement in semen parameters [8-10]. Shoshany et al. further demonstrated that increased T/E ratios significantly and directly correlated with improvement in semen parameters only in their cohort of 21 oligozoospermic men, treated with 1 mg of oral anastrozole daily (8). In our study, we observed sustained increases in T/E ratios for up to 5 months of anastrozole therapy as well as improvement in semen parameters.

While the negative impact of elevated BMI on hormonal parameters has been consistently reported, the same cannot be said for semen parameters. The literature has shown various relationships between BMI and semen parameters, with some studies reporting no correlation, some studies reporting negative changes in specific individual parameters, and other studies finding depression in all semen parameters. In a systematic review and meta-analysis involving 115,158 total participants, Campbell et al. demonstrated that obese men were more likely to experience infertility, have decreased rates of live births per cycle with assisted reproductive technology (ART), and have a 10% absolute risk increase of pregnancy non-viability. In this study, significant differences were not found in conventional semen parameters, but obese men were found to have a higher percentage of sperm with low mitochondrial membrane potential (MMP), DNA fragmentation, and abnormal morphology (12). These findings suggest that while obesity may not affect traditional semen parameters, it may still promote infertility by inducing submicroscopic changes to sperm characteristics.

Our data corroborates much of the findings described in the literature regarding the effects of anastrozole on hormonal and semen parameters. More specifically, we found that in our cohort of overweight and obese men, anastrozole appropriately increased T, decreased E, and increased T/E ratio within 1 month of therapy and remained significantly different at 5 months of therapy. Sperm count, total motile count (TMC), and sperm morphology also showed statistically significant improvement, while semen volume and motility did not. Furthermore, fourteen of 30 (46.6%) subjects achieved pregnancy, with majority conceiving through in vitro fertilization or through intrauterine insemination which suggests that anastrozole may be beneficial with aiding in conception for couples whose male partners are either overweight or obese.

One of the major limitations of this study was the use of BMI as an indicator of adipose tissue mass. Although BMI is widely used to determine an individual’s weight status, it is often done so due to ease of calculation and may not correctly measure adipose content (2). In future studies, alternatives to BMI for body fat composition should be considered, such as the dual-energy X-ray absorptiometry (DXA) scan. Another limitation of this study was that the reproductive status of the female partners was unknown and could not be controlled for since our study was retrospective in nature. Although our findings achieved statistical significance with respect to semen parameters and hormonal profile, the power of our study was low and the efficacy of anastrozole for the treatment of the overweight, or obese subfertile male should be confirmed by a prospective, randomized clinical trial. Additionally, a future prospective, randomized clinical trial regarding response rates to aromatase inhibitors in men with normal BMI versus men with BMI ≥25 kg/m2 would be of great interest as well.

In summary, our study demonstrates improvement in hormonal parameters and semen parameters in subfertile men with BMI over 25. Overall, anastrozole is well tolerated with minimal side effects and may lead to improved pregnancy rates especially in conjunction with in vitro fertilization or intrauterine insemination. Therefore, we recommend anastrozole therapy for overweight or obese, subfertile males with abnormal T/E ratios to further aid in their attempts to achieve pregnancy naturally or with assisted reproductive techniques.

The article’s supplementary files as